Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis.
Identifieur interne : 004A52 ( PubMed/Checkpoint ); précédent : 004A51; suivant : 004A53Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis.
Auteurs : J M Trugman ; R. Leadbetter ; M E Zalis ; R O Burgdorf ; G F WootenSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1994.
English descriptors
- KwdEn :
- Adult, Antipsychotic Agents (adverse effects), Antipsychotic Agents (therapeutic use), Clozapine (adverse effects), Clozapine (therapeutic use), Corpus Striatum (drug effects), Corpus Striatum (physiopathology), Dose-Response Relationship, Drug, Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (physiopathology), Dystonia (chemically induced), Dystonia (drug therapy), Dystonia (physiopathology), Follow-Up Studies, Humans, Long-Term Care, Male, Neurologic Examination (drug effects), Psychotic Disorders (drug therapy), Psychotic Disorders (physiopathology), Receptors, Dopamine D1 (drug effects), Receptors, Dopamine D1 (physiology), Receptors, Dopamine D2 (drug effects), Receptors, Dopamine D2 (physiology).
- MESH :
- chemical , adverse effects : Antipsychotic Agents, Clozapine.
- chemical , drug effects : Receptors, Dopamine D1, Receptors, Dopamine D2.
- chemical , physiology : Receptors, Dopamine D1, Receptors, Dopamine D2.
- chemical , therapeutic use : Antipsychotic Agents, Clozapine.
- chemically induced : Dystonia.
- drug effects : Corpus Striatum, Neurologic Examination.
- drug therapy : Dyskinesia, Drug-Induced, Dystonia, Psychotic Disorders.
- physiopathology : Corpus Striatum, Dyskinesia, Drug-Induced, Dystonia, Psychotic Disorders.
- Adult, Dose-Response Relationship, Drug, Follow-Up Studies, Humans, Long-Term Care, Male.
Abstract
We report a patient with severe axial tardive dystonia who has had dramatic improvement for 4 years after treatment with the atypical antipsychotic drug clozapine (625 mg/day). Clozapine differs from conventional neuroleptics in that it has higher affinity for D1 and lower affinity for D2 dopamine receptors than do conventional antipsychotics, which are relatively selective D2 antagonists. We propose that repetitive stimulation of the D1 receptor by endogenous dopamine, resulting in sensitization of the D1-mediated striatal output in the presence of D2 receptor blockade, is a fundamental mechanism mediating tardive dyskinesia, including the dystonic type. According to this hypothesis, it is primarily the D1 antagonist action of clozapine that accounts for its inability to cause tardive dyskinesia as well as its therapeutic effect in tardive dystonia. Regardless of its mechanism of action, the sustained improvement observed in this case suggests that clozapine should be tried in cases of severe refractory tardive dystonia.
DOI: 10.1002/mds.870090411
PubMed: 7969212
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:7969212Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis.</title><author><name sortKey="Trugman, J M" sort="Trugman, J M" uniqKey="Trugman J" first="J M" last="Trugman">J M Trugman</name><affiliation><nlm:affiliation>Department of Neurology, University of Virginia Health Sciences Center, Charlottesville 22908.</nlm:affiliation><wicri:noCountry code="subField">Charlottesville 22908</wicri:noCountry></affiliation></author><author><name sortKey="Leadbetter, R" sort="Leadbetter, R" uniqKey="Leadbetter R" first="R" last="Leadbetter">R. Leadbetter</name></author><author><name sortKey="Zalis, M E" sort="Zalis, M E" uniqKey="Zalis M" first="M E" last="Zalis">M E Zalis</name></author><author><name sortKey="Burgdorf, R O" sort="Burgdorf, R O" uniqKey="Burgdorf R" first="R O" last="Burgdorf">R O Burgdorf</name></author><author><name sortKey="Wooten, G F" sort="Wooten, G F" uniqKey="Wooten G" first="G F" last="Wooten">G F Wooten</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1994">1994</date><idno type="RBID">pubmed:7969212</idno><idno type="pmid">7969212</idno><idno type="doi">10.1002/mds.870090411</idno><idno type="wicri:Area/PubMed/Corpus">004A80</idno><idno type="wicri:Area/PubMed/Curation">004A80</idno><idno type="wicri:Area/PubMed/Checkpoint">004A52</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis.</title><author><name sortKey="Trugman, J M" sort="Trugman, J M" uniqKey="Trugman J" first="J M" last="Trugman">J M Trugman</name><affiliation><nlm:affiliation>Department of Neurology, University of Virginia Health Sciences Center, Charlottesville 22908.</nlm:affiliation><wicri:noCountry code="subField">Charlottesville 22908</wicri:noCountry></affiliation></author><author><name sortKey="Leadbetter, R" sort="Leadbetter, R" uniqKey="Leadbetter R" first="R" last="Leadbetter">R. Leadbetter</name></author><author><name sortKey="Zalis, M E" sort="Zalis, M E" uniqKey="Zalis M" first="M E" last="Zalis">M E Zalis</name></author><author><name sortKey="Burgdorf, R O" sort="Burgdorf, R O" uniqKey="Burgdorf R" first="R O" last="Burgdorf">R O Burgdorf</name></author><author><name sortKey="Wooten, G F" sort="Wooten, G F" uniqKey="Wooten G" first="G F" last="Wooten">G F Wooten</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1994" type="published">1994</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antipsychotic Agents (adverse effects)</term><term>Antipsychotic Agents (therapeutic use)</term><term>Clozapine (adverse effects)</term><term>Clozapine (therapeutic use)</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (physiopathology)</term><term>Dose-Response Relationship, Drug</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Dyskinesia, Drug-Induced (physiopathology)</term><term>Dystonia (chemically induced)</term><term>Dystonia (drug therapy)</term><term>Dystonia (physiopathology)</term><term>Follow-Up Studies</term><term>Humans</term><term>Long-Term Care</term><term>Male</term><term>Neurologic Examination (drug effects)</term><term>Psychotic Disorders (drug therapy)</term><term>Psychotic Disorders (physiopathology)</term><term>Receptors, Dopamine D1 (drug effects)</term><term>Receptors, Dopamine D1 (physiology)</term><term>Receptors, Dopamine D2 (drug effects)</term><term>Receptors, Dopamine D2 (physiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term><term>Clozapine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine D1</term><term>Receptors, Dopamine D2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Dopamine D1</term><term>Receptors, Dopamine D2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term><term>Clozapine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Dystonia</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Dystonia</term><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Corpus Striatum</term><term>Dyskinesia, Drug-Induced</term><term>Dystonia</term><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Dose-Response Relationship, Drug</term><term>Follow-Up Studies</term><term>Humans</term><term>Long-Term Care</term><term>Male</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We report a patient with severe axial tardive dystonia who has had dramatic improvement for 4 years after treatment with the atypical antipsychotic drug clozapine (625 mg/day). Clozapine differs from conventional neuroleptics in that it has higher affinity for D1 and lower affinity for D2 dopamine receptors than do conventional antipsychotics, which are relatively selective D2 antagonists. We propose that repetitive stimulation of the D1 receptor by endogenous dopamine, resulting in sensitization of the D1-mediated striatal output in the presence of D2 receptor blockade, is a fundamental mechanism mediating tardive dyskinesia, including the dystonic type. According to this hypothesis, it is primarily the D1 antagonist action of clozapine that accounts for its inability to cause tardive dyskinesia as well as its therapeutic effect in tardive dystonia. Regardless of its mechanism of action, the sustained improvement observed in this case suggests that clozapine should be tried in cases of severe refractory tardive dystonia.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">7969212</PMID><DateCreated><Year>1994</Year><Month>12</Month><Day>14</Day></DateCreated><DateCompleted><Year>1994</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>1994</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis.</ArticleTitle><Pagination><MedlinePgn>441-6</MedlinePgn></Pagination><Abstract><AbstractText>We report a patient with severe axial tardive dystonia who has had dramatic improvement for 4 years after treatment with the atypical antipsychotic drug clozapine (625 mg/day). Clozapine differs from conventional neuroleptics in that it has higher affinity for D1 and lower affinity for D2 dopamine receptors than do conventional antipsychotics, which are relatively selective D2 antagonists. We propose that repetitive stimulation of the D1 receptor by endogenous dopamine, resulting in sensitization of the D1-mediated striatal output in the presence of D2 receptor blockade, is a fundamental mechanism mediating tardive dyskinesia, including the dystonic type. According to this hypothesis, it is primarily the D1 antagonist action of clozapine that accounts for its inability to cause tardive dyskinesia as well as its therapeutic effect in tardive dystonia. Regardless of its mechanism of action, the sustained improvement observed in this case suggests that clozapine should be tried in cases of severe refractory tardive dystonia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trugman</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Virginia Health Sciences Center, Charlottesville 22908.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leadbetter</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Zalis</LastName><ForeName>M E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Burgdorf</LastName><ForeName>R O</ForeName><Initials>RO</Initials></Author><Author ValidYN="Y"><LastName>Wooten</LastName><ForeName>G F</ForeName><Initials>GF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017447">Receptors, Dopamine D1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003024">Clozapine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003342">Corpus Striatum</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004421">Dystonia</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008134">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011618">Psychotic Disorders</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017447">Receptors, Dopamine D1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017448">Receptors, Dopamine D2</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7969212</ArticleId><ArticleId IdType="doi">10.1002/mds.870090411</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Burgdorf, R O" sort="Burgdorf, R O" uniqKey="Burgdorf R" first="R O" last="Burgdorf">R O Burgdorf</name><name sortKey="Leadbetter, R" sort="Leadbetter, R" uniqKey="Leadbetter R" first="R" last="Leadbetter">R. Leadbetter</name><name sortKey="Trugman, J M" sort="Trugman, J M" uniqKey="Trugman J" first="J M" last="Trugman">J M Trugman</name><name sortKey="Wooten, G F" sort="Wooten, G F" uniqKey="Wooten G" first="G F" last="Wooten">G F Wooten</name><name sortKey="Zalis, M E" sort="Zalis, M E" uniqKey="Zalis M" first="M E" last="Zalis">M E Zalis</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A52 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 004A52 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:7969212
|texte= Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:7969212" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |